Literature DB >> 25410403

Peritoneal cavity is a route for gut-derived microbial signals to promote autoimmunity in non-obese diabetic mice.

R Emani1, C Alam, S Pekkala, S Zafar, M R Emani, A Hänninen.   

Abstract

Macrophages play a crucial role in innate immune reactions, and peritoneal macrophages (PMs) guard the sterility of this compartment mainly against microbial threat from the gut. Type 1 diabetes (T1D) is an autoimmune disease in which gut microbiota and gut immune system appear to contribute to disease pathogenesis. We have recently reported elevated free radical production and increased permeability of gut epithelium in non-obese diabetic (NOD) mice. Impaired barrier function could lead to bacterial leakage to the peritoneal cavity. To explore the consequences of impaired gut barrier function on extra-intestinal immune regulation, we characterized peritoneal lavage cells from young newly weaned NOD mice. We detected a rapid increase in the number of macrophages 1-2 weeks after weaning in NOD mice compared to C57BL/6 and BALB/c mice. Interestingly, this increase in macrophages was abrogated in NOD mice that were fed an antidiabetogenic diet (ProSobee), which improves gut barrier function. Macrophages in young (5-week-old) NOD mice displayed a poor TNF-α cytokine response to LPS stimulation and high expression of interleukin-1receptor-associated kinase-M (IRAK-M), indicating prior in vivo exposure to TLR-4 ligand(s). Furthermore, injection of LPS intraperitoneally increased T cell CD69 expression in pancreatic lymph node (PaLN), suggestive of T cell activation. Leakage of bacterial components such as endotoxins into the peritoneal cavity may contribute to auto-reactive T cell activation in the PaLN.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25410403     DOI: 10.1111/sji.12253

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  8 in total

Review 1.  The role of the intestinal microbiota in type 1 diabetes mellitus.

Authors:  Mikael Knip; Heli Siljander
Journal:  Nat Rev Endocrinol       Date:  2016-01-04       Impact factor: 43.330

Review 2.  Intestinal dysbiosis and probiotic applications in autoimmune diseases.

Authors:  Gislane Lelis Vilela de Oliveira; Aline Zazeri Leite; Bruna Stevanato Higuchi; Marina Ignácio Gonzaga; Vânia Sammartino Mariano
Journal:  Immunology       Date:  2017-06-29       Impact factor: 7.397

Review 3.  A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.

Authors:  Shokufeh Ghasemian Sorboni; Hanieh Shakeri Moghaddam; Reza Jafarzadeh-Esfehani; Saman Soleimanpour
Journal:  Clin Microbiol Rev       Date:  2022-01-05       Impact factor: 26.132

4.  Lactobacillus rhamnosus Affects Rat Peritoneal Cavity Cell Response to Stimulation with Gut Microbiota: Focus on the Host Innate Immunity.

Authors:  Stanislava Stanojević; Veljko Blagojević; Ivana Ćuruvija; Vesna Vujić
Journal:  Inflammation       Date:  2021-09-10       Impact factor: 4.092

5.  Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset.

Authors:  Frederico R C Costa; Marcela C S Françozo; Gabriela G de Oliveira; Aline Ignacio; Angela Castoldi; Dario S Zamboni; Simone G Ramos; Niels O Câmara; Marcel R de Zoete; Noah W Palm; Richard A Flavell; João S Silva; Daniela Carlos
Journal:  J Exp Med       Date:  2016-06-20       Impact factor: 14.307

6.  The Role of Macrophage Migration Inhibitory Factor in the Function of Intestinal Barrier.

Authors:  Milica Vujicic; Tamara Saksida; Sanja Despotovic; Svetlana Sokovic Bajic; Ivana Lalić; Ivan Koprivica; Dragica Gajic; Natasa Golic; Maja Tolinacki; Ivana Stojanovic
Journal:  Sci Rep       Date:  2018-04-20       Impact factor: 4.379

Review 7.  Intricate Connections between the Microbiota and Endometriosis.

Authors:  Irene Jiang; Paul J Yong; Catherine Allaire; Mohamed A Bedaiwy
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

8.  Early-life fingolimod treatment improves intestinal homeostasis and pancreatic immune tolerance in non-obese diabetic mice.

Authors:  Ling-Ling Jia; Ming Zhang; He Liu; Jia Sun; Li-Long Pan
Journal:  Acta Pharmacol Sin       Date:  2021-01-20       Impact factor: 7.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.